SecBot SecBot
Institutional Cluster

ARQT

Arcutis Biotherapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed10d 14h ago
Institutional cluster: 5 buyers, 2 sellers (bullish)
Actionable Insight • Neutral

The cluster shows conviction from asset managers but lacks insider corroboration and is offset by a $200M ATM. Monitor next 10-Q for continued institutional accumulation and whether the ATM is utilized.

DirectionNeutral
Confidencemedium
Horizonweeks

ZORYVE

▲ Bullish Named in this fund cluster
Impact
Phase
Approved (commercial stage)
Time to market
Already approved and commercialized. The next label expansion (infant atopic dermatitis) has a PDUFA decision date of February 23, 2027.
Next catalyst
PDUFA date · Feb 23, 2027 98d

What to watchThe next hard catalyst is the FDA PDUFA decision on February 23, 2027 for ZORYVE cream 0.05% in infants aged 3-24 months with atopic dermatitis. Approval would expand the addressable patient population and support the company's 2027 revenue inflection narrative; a CRL would remove that near-term growth driver but not threaten the core commercial business, which is already generating over $500M in annual revenue.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$25.55
T+0 close · Nov 6, 2026 · via day close
Latest settled
+10.61%
T+5 · $28.26
Vs SPY
+8.01%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $25.55entry
  2. T+1 · 8d ago +2.54%α +0.18% · $26.20
  3. T+5 · 4d ago +10.61%α +8.01% · $28.26
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Five institutional buyers accumulated $25.0M in ARQT during Q3 2026, led by Principal Financial Group doubling its stake to $21.2M, while two sellers trimmed $3.4M. The cluster follows Q3 earnings that showed ZORYVE revenue growing 45% YoY to $143.9M and raised full-year guidance, though GAAP EPS of $0.06 missed consensus. The net buying signal is tempered by the 45-day reporting lag, the concurrent $200M ATM equity program, and the absence of insider open-market buying.

Key Financial Metrics

Direction
accumulating
Buy Value
$39.7M
Sell Value
$8.0M
Net Flow
$21.6M

Institutional Positions

Net institutional flow: $21.6M

▲ Buyers (5)

InstitutionActionChangePosition ValueValue Δ
Principal Financial GroupDOUBLED+337.5%$21.2M$16.4M
Bank Of New York MellonADD+80.6%$15.8M$7.1M
BarclaysADD+67.4%$2.1M$858.0K

▼ Sellers (2)

InstitutionActionChangePrev ValueValue Δ
CitigroupTRIM-42.2%$4.0M-$1.7M
Vontobel HoldingTRIM-44.5%$4.0M-$1.8M

Key Facts

  • 5 institutional buyers added $25.0M in net new positions during Q3 2026
  • Principal Financial Group doubled its stake (+337.5% shares) to $21.2M
  • Bank Of New York Mellon added 80.6% to reach $15.8M
  • 2 sellers (Citigroup, Vontobel) trimmed a combined $3.4M
  • No insider open-market buying; insider activity shows 4 sells totaling $1.6M in the 30 days before the snapshot
  • Q3 2026 ZORYVE revenue $143.9M (+45% YoY) beat consensus; GAAP EPS $0.06 missed $0.17 consensus
  • $200M ATM equity program filed on same day as earnings

Financial Impact

5 institutions accumulated $25.0M in new positions while 2 reduced holdings by $3.4M; net buying of $21.6M

institutional ownershipfloat

Risk Factors

  • 13F data is 45+ days stale; positions may have been unwound
  • No insider open-market buying to corroborate institutional conviction
  • $200M ATM equity program could dilute existing holders if utilized
  • GAAP EPS miss suggests profitability still below consensus expectations

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-ARQT-2026-Q3

Track record

34 reports on ARQT

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.34% at T+60 after the Aug 5, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $28.26 settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $27.39 settles Feb 8
  3. Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Viewing Entry $25.55 settles Feb 4
  4. Nov 4, 202612d ago 3/A / CLUSTER / 3 Neutral 2/10 Entry $27.00 settles Feb 3
  5. Nov 4, 202612d ago 144 Neutral 3/10 Entry $27.00 settles Feb 3
  6. Nov 4, 202612d ago 424B5 Bearish 4/10 Entry $27.00 settles Feb 3
  7. Nov 4, 202612d ago 8-K Neutral 5/10 No price data
  8. Nov 4, 202612d ago Press Release Mixed 6/10 Entry $27.00 settles Feb 3
  9. Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 settles Feb 1
  10. Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 settles Feb 1
Showing 10 of 34

US Market Status

Market Closed · Opens in 8h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026